Indeed, our findings show that salicylate and the related compound diflunisal exhibit anti-tumor activity against a specific leukemia carrying a t(8;21) translocation, a tumor previously reported to be dependent on p300 in vitro and in vivo (Wang et al., 2011). This evidence concerns the gene EP300 and leukemia.